Trimethoprim-Sulfamethoxazole Therapy For Shigellosis

J. D. Nelson, H. Kusmiesz, L. H. Jackson, E. Woodman

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

Twenty-eight infants and children hospitalized for severe shigellosis were treated orally either with ampicillin trihydrate (100 mg/kg/day administered in divided doses every six hours) or with trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours) for five days. Four patients with ampicillin-resistant shigellae continued to have diarrhea and positive stool cultures during therapy. Patients with susceptible shigellae treated with ampicillin and all patients treated with trimethoprim-sulfamethoxazole responded promptly and comparably within an average of 1.6 and 1.7 days, respectively, until stool cultures were negative, and 3.1 and 2.9 days, respectively, until diarrhea stopped. Patients with ampicillin-resistant shigellae responded to treatment with trimethoprim-sulfamethoxazole. It is concluded that trimethoprimsulfamethoxazole is the best currently available drug for treatment of shigellosis in areas where multiple antibiotic resistance of shigellae is common.

Original languageEnglish (US)
Pages (from-to)1239-1243
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Volume235
Issue number12
DOIs
StatePublished - Mar 22 1976

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Trimethoprim-Sulfamethoxazole Therapy For Shigellosis'. Together they form a unique fingerprint.

Cite this